PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan New Product Innovation Award Conferred on Mibelle Biochemistry for SunActin - Unique SunActin offers Anti-ageing and Sun Protection Properties
Frost & Sullivan New Product Innovation Award Conferred on Mibelle Biochemistry for SunActin

 

NewswireToday - /newswire/ - London, United Kingdom, 2011/09/05 - Unique SunActin offers Anti-ageing and Sun Protection Properties.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The 2011 Frost & Sullivan Europe New Product Innovation Award in Dermatological Active Ingredients is presented to Mibelle Biochemistry for its intelligent cell protecting factor, SunActin.

"SunActin is an active ingredient designed to complement sun care products, as it can counteract the negative effects of UVA and UVB radiation as well as the negative side effects of sunscreens, while additionally protecting the skin," notes Frost & Sullivan Research Analyst Vin Nee.

SunActin is set to make strong gains as awareness about the need for sun protection and early prevention of ageing among both male and female populations rises. Furthermore, market trends are moving towards natural-derived product platforms, such as those offered by SunActin.

The dual benefits of sun protection and anti-ageing, have underlined its appeal. This unique product can be used in personal care product formulations for both young and mature consumers.

"SunActin, with potential sun protection and anti-ageing features, is proven by both in vitro and in vivo studies," remarks Nee. "The incorporation of SunActin into the product formulation of sunscreens exhibits enhancement of the protective effect of sunscreens in vivo. The ex vivo studies of SunActin treatment reveal its ability to boost the skin's defence capacity and protect it from UV induced oxidative stress through DNA microarray screening."

SunActin's anti-ageing property works by energising the skin cells and delaying ageing mechanisms. At the same time, it exerts skin protection in the sunscreen by radical scavenging properties and by enhancing SPF levels.

SunActin is derived from a combination of organic sunflower sprouts and a nanoemulsion of natural tocopherol. The sunflower shoot extract is carefully purified to be compatible with the nanoemulsion to ensure the product's stability and optimal delivery of the active ingredients to the skin structure.

"Strategic product positioning in accordance with the company's motto of ‘inspired by nature- realized by science' has enabled Mibelle Biochemistry to forge a new path in the field of dermatological active ingredients," concludes Nee. "Such efforts, as exemplified by SunActin, make Mibelle Biochemistry an obvious choice for this Frost & Sullivan accolade."

The New Product Innovation Award is presented to the company that has excelled in the following criteria: innovative element of the product, leverage leading edge technologies in product, value added features/benefits, increased customer ROI (small change) and customer acquisition/penetration potential.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Mibelle Biochemistry

Mibelle Biochemistry (mibellebiochemistry.com), a Swiss company, is specialized in the research and development of innovative, high-quality actives for the cosmetic industry. Inspired by nature Mibelle Biochemistry transforms naturally derived compounds into truly functional cosmetic ingredients. Furthermore Mibelle Biochemistry possesses powerful encapsulation technologies that guarantee optimum bioavailability. All products are accompanied by comprehensive technical support and marketing-oriented documentation.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan New Product Innovation Award Conferred on Mibelle Biochemistry for SunActin

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Catherine Brassell 
+44(0)20 7195 7867 catherine.brassell@frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)